生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild type receptor. It inhibited cellular p-EGFR-Y1173 with IC50 values of 2nM, 163nM and >10μM for H1975 (L858R T790M), H3255 (L858R) and HaCaT (WT), respectively. It almost completely depleted p-EGFR-Y1068 at concentration of 20μM in NIH-3T3 cells expressing L858R/T790M EGFR. But it is not effective in blocking EGFR-driven proliferation in cells as a single agent due to differential potency on the two subunits of the dimeric receptor, which interact in an asymmetric manner in the active state. Combination with cetuximab which blocks EGFR dimerization could potentiate the effect of EAI045 on mouse models of lung cancer driven by L858R/T790M EGFR and by L858R/T790M/C797S EGFR, a mutant that is resistant to all currently available EGFR TKIs[2]. | ||
作用机制 | EAI045 binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of EGFR. EAI045 is an allosteric inhibitor, which distinguished it from current EGFR TKIs target the ATP-site of the kinase.[2] |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.61mL 0.52mL 0.26mL |
13.04mL 2.61mL 1.30mL |
26.08mL 5.22mL 2.61mL |
参考文献 |
---|